Dong-Gu Biopharm to Collaborate with Pelmore and Link Korea on Next-Generation Drug Delivery Technology
Predicted impact: Low· Actual: −6.0% vs sector, volume 1.0× normal (5 trading days)
DongKoo Bio & Pharma동구바이오제약
006620 · KOSDAQ · ₩006620 · 동구바이오제약
₩3,310▲ ₩125 (3.92%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −40.04%
- Market cap
- ₩94B
- Enterprise value
- ₩165B
- P/E
- 2.9×
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- 23.2%
- Net margin
- 13.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−47.5% from the high
₩3,055Today: ₩3,055 – ₩3,310₩6,300
Returns
- 1W−2.9%
- 1M−6.1%
- 3M−9.1%
- 6M−36.3%
- YTD−39.5%
- 1Y−40.0%
- Volume today
- 270,812
- 5.0× the 20-day average
- Traded today
- ₩852M
- Listed shares
- 28,464,992
- EPS (12 months)
- ₩1,160
- Earnings yield 35.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+3.9% on Oct 28, 2026. Trading value 4.6× its normal.
DongKoo Bio & Pharma filed reports on October 28, 2026 about ending a trust contract for buying back its own shares. The company also decided to cancel those shares. These filings are routine corporate steps and do not show a clear change in the business.
AI summary of the news and filings linked. It can be wrong; check them.
- • Filing: Trust Contract Termination Result Report
- • Filing: Share cancellation decision
- • Filing: Material Matters Report (Decision on Termination of Trust Agreement for Own Share Acquisition)
- • Foreign investors bought a net ₩32M that day
- • Buzz 65 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Warming up- BuzzRisingBuzz 65: heavy trading.
- SentimentMixedNews: The filings describe routine share buyback and cancellation steps with no clear good or bad news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-6% over the last month; the price is below its 20-day average.
- News impactSome7 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
DongKoo Bio & Pharma stock overview
DongKoo Bio & Pharma (동구바이오제약, KRX: 006620) is listed on KOSDAQ, in the Biotech & Pharma sector. The company operates through several segments, including pharmaceutical and quasi-drug manufacturing and sales (prescription drugs, CMO services, medical devices and cosmetics), new technology business financing through its wholly owned subsidiary Loftyrock Investment, medical services and medical tourism for foreign patients through its 51%-owned subsidiary Wholegate, and wholesale and consulting of pharmaceuticals, medical devices, cosmetics, health functional foods and general foods, with operations in Mongolia through Dongkoo Bio & Pharma and Moshea Medical. Its shares closed at ₩3,310 on Oct 28, 2026, up 3.92% on the day, giving it a market value of ₩94B.
Key facts
- Market cap
- ₩94B
- Sector
- Biotech & Pharma
- Latest price change
- +3.92%
- As of
- Oct 28, 2026
- Main business
- The company operates through several segments, including pharmaceutical and quasi-drug manufacturing and sales (prescription drugs, CMO services, medical devices and cosmetics), new technology business financing through its wholly owned subsidiary Loftyrock Investment, medical services and medical tourism for foreign patients through its 51%-owned subsidiary Wholegate, and wholesale and consulting of pharmaceuticals, medical devices, cosmetics, health functional foods and general foods, with operations in Mongolia through Dongkoo Bio & Pharma and Moshea Medical.
Quick answers about DongKoo Bio & Pharma
- What does DongKoo Bio & Pharma do?
- The company operates through several segments, including pharmaceutical and quasi-drug manufacturing and sales (prescription drugs, CMO services, medical devices and cosmetics), new technology business financing through its wholly owned subsidiary Loftyrock Investment, medical services and medical tourism for foreign patients through its 51%-owned subsidiary Wholegate, and wholesale and consulting of pharmaceuticals, medical devices, cosmetics, health functional foods and general foods, with operations in Mongolia through Dongkoo Bio & Pharma and Moshea Medical. Its main pharmaceutical products include Dermotason MLE, Cycrin soft capsules, and Europa sustained-release tablets.
- What is the market cap of DongKoo Bio & Pharma?
- The market capitalisation of DongKoo Bio & Pharma was ₩94B at the close on Oct 28, 2026.
- Who are the largest shareholders of DongKoo Bio & Pharma?
- According to the latest official filings, the largest reported holders are Jo Yong-jun (37.18%, as of Oct 19, 2026); Lee Gyeong-ok (6.26%, as of Mar 19, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.20%, as of Jul 31, 2026).
- When is the next earnings report from DongKoo Bio & Pharma?
- Korean companies rarely announce results dates in advance. Based on when DongKoo Bio & Pharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company operates through several segments, including pharmaceutical and quasi-drug manufacturing and sales (prescription drugs, CMO services, medical devices and cosmetics), new technology business financing through its wholly owned subsidiary Loftyrock Investment, medical services and medical tourism for foreign patients through its 51%-owned subsidiary Wholegate, and wholesale and consulting of pharmaceuticals, medical devices, cosmetics, health functional foods and general foods, with operations in Mongolia through Dongkoo Bio & Pharma and Moshea Medical. Its main pharmaceutical products include Dermotason MLE, Cycrin soft capsules, and Europa sustained-release tablets.
Written by AI from the company's latest annual report.
- Korean name
- 동구바이오제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 조용준
- Founded
- Jul 1983
- Listed
- Feb 2018
- Listed shares
- 28,464,992
- Fiscal year ends
- Month 12
- Website
- www.dongkoo.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Dongkoo Bio & Pharma Forms Three-Way Partnership on Next-Generation Drug Delivery Technology, "Expanding High-Value Business"
Predicted impact: Low· Actual: −6.0% vs sector, volume 1.0× normal (5 trading days)
Three-way drug delivery tech partnership; no financial terms disclosed
Recent filings
See all- Share cancellation decisionOct 28, 2026
- Trust Contract Termination Result ReportOct 28, 2026
- Material Matters Report (Decision on Termination of Trust Agreement for Own Share Acquisition)Oct 28, 2026
- Status Report on Acquisition Under Trust AgreementOct 22, 2026
- 5%+ holding reportOct 19, 2026
Titles in Korean until English translations are added.
Also known as: DongKoo Bio & Pharma / 동구바이오제약 / 006620 / KRX:006620
Source: KRX statistical information